



Advances in Glycoconjugate Vaccines and Nanovaccines

Guest Editors:

Prof. Dr. Marco Terreni

Department of Drug Sciences,
School of Pharmacy, University of
Pavia, Via Taramelli 12, 27100
Pavia, Italy

Dr. Sara Tengattini

Department of Drug Sciences,
University of Pavia, Via Taramelli
12, 27100 Pavia, Italy

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editors

Glycoconjugate vaccines, obtained by linking carbohydrates to protein carriers, have had a critical role in fighting infectious diseases and, despite the new mRNA-based technologies, still are a valuable strategy to develop anti-infection and anti-cancer vaccines, from preclinical to clinical stages. Indeed, they are particularly effective in targeting carbohydrates, which are one of the most important classes of surface antigens, and which can also be used as adjuvants to promote immunostimulant effects as well as for promoting antigen or nucleic acid delivery for vaccine development.

This Special Issue will focus on recent advancements in the design, development, and characterization of glycosylated proteins and nanoparticles as potential vaccines. The Special Issue is open to original research articles and reviews on antigenic/immunogenic oligosaccharides or new glyco-derivatives, as well as pre-clinical and clinical studies on anti-infection or anticancer glyco-(nano)vaccines. Investigations on analytical approaches to support the design and production of glycoconjugates will also be considered.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com